Skip to Main Content

A rheumatoid arthritis drug from Incyte (INCY), once expected to result in blockbuster sales, has won approval for only a narrow group of patients and will carry a label warning of serious safety risks that are likely to limit its market potential.

The pill, to be marketed as Olumiant, won Food and Drug Administration approval Friday, a minor consolation for Incyte and partner Eli Lilly (LLY) as the companies adjust their revenue expectations for the drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED